Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Positive Results of QMF149 Clinical Trials Unveiled by Novartis

Novartis has unveiled positive phase 3 data for its dual combination asthma drug QMF149, strengthening its case for approval with regulators.  The asthma combination regimen, QMF149, is a once-dail...

Novartis to Submit 80 Major Marketing Applications for its Drugs from 2020 to 2022

novartis
Novartis said Thursday ahead of a meeting with analysts and investors that it expects to submit more than 80 major marketing applications for its drugs from 2020 to 2022 in the US, Europe, Japan and C...

Novartis Opened New Manufacturing Facility for Cell and Gene Therapies in Switzerland

Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland. The new facility also facilitates the production of advanced a...

Pfizer, Novartis and 11 Drugmakers Set Aside $2bn to Invest in Gene Therapy Manufacturing

gene therapy
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control the ...

FDA Approved Adakveo for Frequency of Vaso-Occlusive Crisis Reduction

The U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease tha...

Novartis to Broaden Patient Reach and Availability of Portfolio of Medicines in sub-Saharan Africa

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in th...

U.S. Regulators Halted Trial of Novartis’s Zolgensma Treatment

fda office
U.S. regulators have halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety concerns, the company said, in a setback for the drugmaker’s plan to expand its use to older p...

MorphoSys, Novartis and Galapagos Announced Premature End to Clinical Development Program of MOR106

novartis
MorphoSys, Novartis and Galapagos have announced the premature end of the clinical development program of MOR106 in atopic dermatitis, citing “low probability to meet the main goal of study.” The f...

Sixth Element Capital and CR UK Announced Multi-Year Agreement with Novartis

partnership
Sixth Element Capital and the Cancer Research UK (CR UK) Beatson Institute have announced a multi-year agreement with Novartis to progress the development of novel RAS inhibitors, discovered by the In...

European Commission Approved Label Update for Up-Titration of Cosentyx

European-Commission
Novartis, a leader in rheumatology and immuno-dermatology, announced today that the European Commission (EC) has approved a label update for the up-titration of Cosentyx (secukinumab) to 300 mg for pa...

Pliant Therapeutics Signed Strategic Collaboration and License Agreement with Novartis

cooperation handshake
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, announced it has entered into a strategic col...

Novartis Presented Positive Results from Phase III Study of Jakavi®

Novartis announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease (GvHD). The study met i...

Cosentyx® Treatment Results Show Sustained Improvement in Symptoms of Psoriatic Arthritis

Novartis, a leader in rheumatology and immuno-dermatology, announced results for Cosentyx from a pooled-analysis that shows sustained improvement in signs and symptoms of psoriatic arthritis, particul...

Novartis Confirm High Efficacy and Favorable Safety Profile of Cosentyx®

clinical-trial
Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice. Data from five real-world evidence (RWE) and observational st...

FDA Approved Beovu® Injection

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Beovu® (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD). Beov...

Novartis Announce Positive Results of Lugelizumab Trials

clinical trials
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg. Results from a Phase IIb dose-finding study show an avera...